Impact of Treatment with GLP1 Receptor Agonists, Liraglutide 3.0 mg and Semaglutide 1.0 mg, While on a Waiting List for Bariatric Surgery

• Published in: Biomedicines Vol. 11; no. 10; p. 2785
• Main Authors: Rubio-Herrera, Miguel A, Mera-Carreiro, Sara, Sánchez-Pernaute, Andrés, Ramos-Levi, Ana M
• Format: Journal Article
• Language: English
• Published: Basel MDPI AG 01-10-2023; MDPI
• Subjects: Agonists; bariatric surgery; Care and treatment; Cholesterol; Diabetes; Drug dosages; Gastrointestinal surgery; Liraglutide; Metabolism; Mortgage-backed securities; Obesity; Patients; semaglutide; severe obesity; Sibutramine; Surgery; Surgical anastomosis; Surgical outcomes; Type 2 diabetes; Variables; waiting list; Weight; Weight control; Spain
• ISSN: 2227-9059; 2227-9059
• DOI: 10.3390/biomedicines11102785

Background: Weight loss before undergoing metabolic and bariatric surgery (MBS) has been suggested to reduce perioperative complications, although with controversial results. The objective of this study is to evaluate the impact of treatment with GLP1-R agonists (liraglutide 3.0 mg and semaglutide 1.0 mg) on preoperative weight loss and patients’ decisions regarding MBS while on a surgical waiting list. Materials and methods: One hundred and two patients on a waiting list for MBS started treatment with GLP1-RA for at least 6 months. Changes in weight at 26 and 52 weeks, the number of patients achieving >5% weight loss, and patients’ decisions regarding MBS were evaluated. Results: After 52 weeks, patients lost 16.9 ± 7.2% of weight with semaglutide 1.0 mg and 16.1 ± 5.8% of weight with liraglutide 3.0 mg. All patients lost ≥5% of initial weight, 84.7% lost ≥10%, 54.6% lost ≥15%, and 27.5% reached ≥20%. A total of 68.6% of participants were satisfied with the achieved weight loss and withdrew from the waiting list for MBS. A threshold of >15.1% weight loss had the greatest sensitivity and specificity for the final decision regarding undergoing MBS. Conclusions: Losing >15% of initial weight after 52 weeks of treatment with liraglutide 3.0 mg or semaglutide 1.0 mg during the waiting list for MBS impacts patients’ decisions regarding the final acceptance or rejection of the procedure.